Ossianix: Shark teeth
Ossianix's small shark-derived antibodies could access tough neuronal targets
Ossianix Inc. is developing small shark-derived single domain antibodies that could access hard to hit neuronal targets. The company is working with H. Lundbeck A/S to develop specific inhibitors of pain target P2X3 and to optimize additional antibodies that can be delivered across the blood-brain barrier.
"IgG can do very many things, but there are areas of potential for biologics that are unmet needs, particularly in difficult targets in the central nervous system," said Ossianix co-founder and CEO Frank Walsh.
Walsh was EVP and head of discovery research